Hyperaldosteronism caused by drospirenone and ethinylestradiol tablets: a case report
10.3760/cma.j.cn114452-20230810-00053
- VernacularTitle:屈螺酮炔雌醇片导致高醛固酮血症1例
- Author:
Liling LIN
1
;
An SONG
;
Xiaoli MA
;
Yutong ZOU
;
Wei LUO
;
Shaowei XIE
;
Songlin YU
;
Wei XIONG
;
Ling QIU
Author Information
1. 中国医学科学院，北京协和医院检验科，北京 100730
- Keywords:
Hyperaldosteronism;
Drospirenone;
Ethinyl estradiol
- From:
Chinese Journal of Laboratory Medicine
2024;47(5):574-577
- CountryChina
- Language:Chinese
-
Abstract:
A young female patient with acne and elevated testosterone level underwent plasma steroid hormones testing and found a significant increase in aldosterone. We excluded testing interference and verified the absence of hypertension, hypokalemia, and adrenal occupancy, as well as primary and secondary hyperaldosteronism. During follow-up, a temporal correlation was found between aldosterone levels and the use of drospirenone and ethinylestradiol tablets. It was observed that the combination of drospirenone and ethinylestradiol could lead to the increase of aldosterone level and the concentration ratio of aldosterone to direct renin through different mechanisms. Drospirenone exerts an antagonistic effect on mineralocorticoid receptor to prevent the development of hypertension or hypokalemia. In clinical practice, it is necessary to pay attention to the effect of this drug on screening markers for primary aldosteronism. In the laboratory examination, when female patients with no symptoms of hypertension and hypokalemia but with elevated aldosterone levels are encountered, it can be verified whether they have a history of use of compound estrogen-progestin such as drospirenone and ethinylestradiol tablets, and appropriate tips are provided in the report.
